GLPwatch
Methodology Study To Examine 6-Week Food Intake With Liraglutide In Obese Subjects
NCT03041792 · Completed
Last updated 2026-05-28This clinical trial studied how taking the medication liraglutide for 6 weeks affected the amount of food eaten by adults with obesity during two lunchtime meals.
Status Completed The study has finished.
Phase Phase 1 Checks safety and dosing in a small group.
Type Interventional (clinical trial)
Design Randomized, double-blind basic-science study
Participants 61 people
Who can join Ages 18–75 · all sexes
Timeline Started 2017-02 · est. completion 2018-01
Where 1 site · United States
What this study is testing ClinicalTrials.gov NCT03041792 ↗
Description as written by the study sponsor.
This will be a randomized, double blind, placebo controlled, 2 arm, parallel group, methodology study to assess the effect of 6 weeks of liraglutide administration on food intake in obese subjects.
Treatments tested
- Liraglutide Drug
Liraglutide
- Placebo Other
Placebo
| Main thing measured | Change From Baseline (Visit 3) in Mean Energy Intake During Ad Libitum Lunches at Visits 4 and 5 |
|---|---|
| Sponsor | Pfizer |
| Conditions studied | Obesity |
| GLP-1 drugs | liraglutide |
Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT03041792 ↗